Baseline characteristics
| n (%) | |
|---|---|
| Gender | Cases, n (%) |
| Male | 43 (44.8) |
| Female | 53 (55.2) |
| Age (years) | Cases, n (%) |
| <40 | 4 (4.2) |
| 40–50 | 15 (15.6) |
| 50–60 | 29 (30.2) |
| >60 | 48 (50) |
| Tumour quadrant | Eyes, n (%) |
| Temporal | 10 (9.1) |
| Nasal | 9 (8.3) |
| Superior | 8 (7.3) |
| Inferior | 9 (8.3) |
| Super-nasal | 9 (8.3) |
| Supero-temporal | 8 (7.3) |
| Infero-nasal | 5 (4.6) |
| Infero-temporal | 5 (4.6) |
| Macula | 46 (42.2) |
| Tumour height (mm) | Eyes, n (%) |
| <3 | 66 (60.6) |
| 3–6 | 28 (25.7) |
| >6–9 | 9 (8.2) |
| >9 | 6 (5.5) |
| Largest basal tumour diameter (mm) | Eyes, n (%) |
| <10 | 48 (44) |
| 10–13 | 20 (18.4) |
| >13–15 | 18 (16.5) |
| 16–18 | 8 (7.3) |
| >18 | 15 (13.8) |
| Visual acuity | Eyes, n (%) |
| 6/6–6/9 | 31 (28.5) |
| <6/9–6/24 | 30 (27.5) |
| <6/24–6/60 | 24 (22) |
| <6/60-HM | 24 (22) |
| Tumour localisation | Eyes, n (%) |
| Choroid | 97 (89) |
| Iris | 10 (9.2) |
| Ciliary body | 3 (2.8) |